Pairidex raised $4.89 million in oversubscribed seed financing to support FusionMRD, an RNA-based droplet digital PCR blood test for monitoring minimal residual disease in gene fusion-driven blood cancers. The company said the test is already commercially available through its CLIA- and CAP-accredited lab and will use the new capital to accelerate commercialization and clinical studies, starting with acute myeloid leukemia.